Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03876301 · ClinicalTrials.gov registry record
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
A clinical trial, sponsored by Spark Therapeutics.
- Completed
- Registry status
- 25
- Enrollment target
NCT03876301 is a clinical trial that has completed, run by Spark Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT03876301 has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The aim of this prospective, observational study is to establish a dataset on the frequency of bleeding events, as well as other characteristics of bleeding events and FVIII infusions, in patients with clinically severe hemophilia A receiving prophylactic FVIII replacement therapy as standard of care. The data collected from this study may assist in providing baseline information for comparison to the Spark's investigational hemophilia A gene therapy in future Phase 3 studies.
Interventions
- DRUG Standard of Care FVIII Replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-01-21 |
| Est. Completion | 2023-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03876301
The ClinicalTrials.gov registry entry for NCT03876301 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spark Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care FVIII Replacement therapy is the first listed.
NCT03876301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03876301 about?
NCT03876301 is a clinical study titled "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants". The aim of this prospective, observational study is to establish a dataset on the frequency of bleeding events, as well as other characteristics of bleeding events and FVIII infusions, in patients with clinically severe hemophilia A receiving prophylactic FVIII replacement therapy as standard of car...
What is the current status of trial NCT03876301?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2019-01-21. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT03876301?
The interventions under investigation include: Standard of Care FVIII Replacement therapy (DRUG).
Who is sponsoring clinical trial NCT03876301?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.